Argenx Se (ARGX) Other Non Operating Income (2016 - 2026)
Argenx Se's (ARGX) quarterly Other Non Operating Income came in at -$8.0 million in Q2 2026, down 116.47% YoY from $48.6 million in Q2 2025, and up 27.27% on a QoQ basis from -$11.0 million in Q1 2026.
Argenx Se (ARGX) Other Non Operating Income (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Other Non Operating Income data on file, last reported at -$8.0 million in Q2 2026.
- Quarterly Other Non Operating Income fell 116.47% year-over-year to -$8.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$29.2 million (down 153.53% YoY) and the FY2025 annual result came in at $65.8 million, up 236.47% from the prior year.
- Other Non Operating Income climbed to -$8.0 million in Q2 2026, from -$11.0 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $60.3 million in Q4 2022 to a low of -$54.9 million in Q4 2024.
- A 5-year average of -$1.1 million and a median of -$7.6 million in 2022 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income tumbled 542.15% — and 2025, when it jumped 714.51%.
- Tracing ARGX's Other Non Operating Income over 5 years: stood at $60.3 million in 2022, then tumbled by 37.9% to $37.4 million in 2023, then tumbled by 246.78% to -$54.9 million in 2024, then jumped by 84.77% to -$8.4 million in 2025, then advanced by 4.34% to -$8.0 million in 2026.
- The last three Other Non Operating Income figures came in at -$8.0 million (Q2 2026), -$11.0 million (Q1 2026), and -$8.4 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.00 Mn |
| Mar 31, 2026 | -11.00 Mn |
| Dec 31, 2025 | -8.36 Mn |
| Sep 30, 2025 | -1.85 Mn |
| Jun 30, 2025 | 48.57 Mn |
| Mar 31, 2025 | 27.00 Mn |
| Dec 31, 2024 | -54.92 Mn |
| Sep 30, 2024 | 33.93 Mn |
| Jun 30, 2024 | -7.90 Mn |
| Mar 31, 2024 | -19.31 Mn |
| Dec 31, 2023 | 37.42 Mn |
| Sep 30, 2023 | -32.51 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Mar 31, 2023 | 11.17 Mn |
| Dec 31, 2022 | 60.26 Mn |
| Sep 30, 2022 | -39.61 Mn |
| Jun 30, 2022 | -46.17 Mn |
| Mar 31, 2022 | -7.21 Mn |
| Dec 31, 2021 | -14.06 Mn |
| Sep 30, 2021 | -17.62 Mn |